Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Муколитическая терапия амброксолом: новая лекарственная парадигма «7+7»
Муколитическая терапия амброксолом: новая лекарственная парадигма «7+7»
С.Л.Бабак, М.В.Горбунова, А.Г.Малявин. Муколитическая терапия амброксолом: новая лекарственная парадигма «7+7».
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Кун Т. Структура научных революций. М.: Прогресс, 1977.
2. Rogers DF. Mucoactive agents for airway mucus hypersecretory diseases. Respir Care 2007; 52 (9): 1176–97.
3. Wirtz HR. Effekt von Ambroxol auf die Surfactantsekretion und synthese von isolierten, alveolaren Typ II-Zellen. Pneumologie 2000; 54: 278–83.
4. Oliveri D, Zavattini G, Tomasini G et al. Ambroxol for the prevention of chronic bronchitis exacerbations: Long-term multicenter trial. Respiration 1987; 51 (Suppl.): 42–51.
5. Gillissen A, Nowak D. Characterization of N-acetylcysteine and ambroxol in anti-oxidant therapy. Respir Med 1998; 92: 609–23.
6. Nowak D, Antczak A, Krol M et al. Antioxidant properties of ambroxol. Free Rad Biol Med 1994; 16: 517–22.
7. Weiser T, Wilson N. Inhibition of tetrodotoxin (TTX)-resistant and TTX-sensitive neuronal Na+ channels by the secretolytic ambroxol. Mol Pharmacol 2002; 62 (3): 433–8, 76.
8. Pauwels RA, Anthonisen N, Bailey WC et al. GOLD scientific committee. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: updated 2009: 1–55.
9. An open, long-term, multicenter study in 5635 patients. Prevention of chronic bronchitis exacerbations with ambroxol (mucosolvan retard). Respiration 1989; 55 (Suppl.): 84–96.
10. Poole PJ, Black PN. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary diseases: systematic review. BMJ 2001; 322: 1271–3.
11. Ekberg-Jansson A, Larsson S, Lofdahl CG. Preventing exacerbations of chronic bronchitis and COPD. BMJ 2001; 322: 1259–61.
12. Ratjen F, Wonne R, Posselt HG et al. A double-blind placebo controlled trial with oral ambroxol and N-acetylcysteine for mucolytic treatment in cystic fibrosis. Eur J Pediatr 1985; 144: 374–7.
13. Caramina G, Gagliardini R, Ruffini E et al. The management of cystic fibrosis with carbocysteine lysine salt: single blind comparative study with ambroxol hydrochloride. J Int Med Res 1995; 23: 284–93.
14. Luerti M, Lazzarin A, Corbella E et al. An alternative to steroids for prevention of respiratory distress syndrome (RDS): Multicenter controlled study to compare ambroxol and betamethasone. J Perinat Med 1987; 15: 227–38.
15. Wauer RR, Schmalisch G, Bohme B et al. randomized double blind trial of ambroxol for the treatment of respiratory distress syndrome. Eur J Pediatr 1992; 151: 357–63.
16. Siergiejko Z, Obrzut D, Rogalewska A. Value of ambroxol in treatment of bronchial asthma and spastic bronchitis. Pol Tyg Lek 1991; 46: 424–7.
17. Fegiz G. Prevention by ambroxol of broncho-pulmonary complications after upper abdominal surgery: double blind Italian multicenter clinical study versus placebo. Lung 1991; 169: 69–76.
18. Hashizume T. Pulmonary alveolar proteinosis successfully treated with ambroxol. Intern Med 2002; 41: 1175–8.
19. Szmeja Z, Golusinski W, Mielcarek-Kunchta D et al. Use of mucolytic preparations (Mucosolvan) in selected diseases of the upper respiratory tract. Part II. Otolaryngol Pol 1997; 5: 480–6.
20. Perez-Neria J, Garcia Rubi E. Ambroxol-amoxiciline fixed combination vs. amoxiciline in acute infectious respiratory conditions - comparative study of antibiotic levels in bronchial mucus and blood. Compend Invest Clin Lat Arn 1992; 12: 5–10.
21. Malerba M, Ponticiello A, Radaeli A et al. Effect of twelve-months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double-blind, randomized, multicenter, placebo-controlled study (the AMETHIST Trial). Pulm Pharmacol Ther 2004; 17: 27–34.
22. Franklin B. Collected and edited with a life and introduction by Albert Henry. Macmillan & CO, LTD. London 1906; 6 (1773–6): 676. On Catching Cold 1773; 62.
23. Davidson, Tish, Teresa G. Odle. «Common Cold». The Gale Encyclopedia of Medicine 2, Detroit: Gale 2006; p. 955–9.
24. Revision of the International Classification of Diseases (ICD). World Health Organization. Retrieved 2010.
2. Rogers DF. Mucoactive agents for airway mucus hypersecretory diseases. Respir Care 2007; 52 (9): 1176–97.
3. Wirtz HR. Effekt von Ambroxol auf die Surfactantsekretion und synthese von isolierten, alveolaren Typ II-Zellen. Pneumologie 2000; 54: 278–83.
4. Oliveri D, Zavattini G, Tomasini G et al. Ambroxol for the prevention of chronic bronchitis exacerbations: Long-term multicenter trial. Respiration 1987; 51 (Suppl.): 42–51.
5. Gillissen A, Nowak D. Characterization of N-acetylcysteine and ambroxol in anti-oxidant therapy. Respir Med 1998; 92: 609–23.
6. Nowak D, Antczak A, Krol M et al. Antioxidant properties of ambroxol. Free Rad Biol Med 1994; 16: 517–22.
7. Weiser T, Wilson N. Inhibition of tetrodotoxin (TTX)-resistant and TTX-sensitive neuronal Na+ channels by the secretolytic ambroxol. Mol Pharmacol 2002; 62 (3): 433–8, 76.
8. Pauwels RA, Anthonisen N, Bailey WC et al. GOLD scientific committee. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: updated 2009: 1–55.
9. An open, long-term, multicenter study in 5635 patients. Prevention of chronic bronchitis exacerbations with ambroxol (mucosolvan retard). Respiration 1989; 55 (Suppl.): 84–96.
10. Poole PJ, Black PN. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary diseases: systematic review. BMJ 2001; 322: 1271–3.
11. Ekberg-Jansson A, Larsson S, Lofdahl CG. Preventing exacerbations of chronic bronchitis and COPD. BMJ 2001; 322: 1259–61.
12. Ratjen F, Wonne R, Posselt HG et al. A double-blind placebo controlled trial with oral ambroxol and N-acetylcysteine for mucolytic treatment in cystic fibrosis. Eur J Pediatr 1985; 144: 374–7.
13. Caramina G, Gagliardini R, Ruffini E et al. The management of cystic fibrosis with carbocysteine lysine salt: single blind comparative study with ambroxol hydrochloride. J Int Med Res 1995; 23: 284–93.
14. Luerti M, Lazzarin A, Corbella E et al. An alternative to steroids for prevention of respiratory distress syndrome (RDS): Multicenter controlled study to compare ambroxol and betamethasone. J Perinat Med 1987; 15: 227–38.
15. Wauer RR, Schmalisch G, Bohme B et al. randomized double blind trial of ambroxol for the treatment of respiratory distress syndrome. Eur J Pediatr 1992; 151: 357–63.
16. Siergiejko Z, Obrzut D, Rogalewska A. Value of ambroxol in treatment of bronchial asthma and spastic bronchitis. Pol Tyg Lek 1991; 46: 424–7.
17. Fegiz G. Prevention by ambroxol of broncho-pulmonary complications after upper abdominal surgery: double blind Italian multicenter clinical study versus placebo. Lung 1991; 169: 69–76.
18. Hashizume T. Pulmonary alveolar proteinosis successfully treated with ambroxol. Intern Med 2002; 41: 1175–8.
19. Szmeja Z, Golusinski W, Mielcarek-Kunchta D et al. Use of mucolytic preparations (Mucosolvan) in selected diseases of the upper respiratory tract. Part II. Otolaryngol Pol 1997; 5: 480–6.
20. Perez-Neria J, Garcia Rubi E. Ambroxol-amoxiciline fixed combination vs. amoxiciline in acute infectious respiratory conditions - comparative study of antibiotic levels in bronchial mucus and blood. Compend Invest Clin Lat Arn 1992; 12: 5–10.
21. Malerba M, Ponticiello A, Radaeli A et al. Effect of twelve-months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double-blind, randomized, multicenter, placebo-controlled study (the AMETHIST Trial). Pulm Pharmacol Ther 2004; 17: 27–34.
22. Franklin B. Collected and edited with a life and introduction by Albert Henry. Macmillan & CO, LTD. London 1906; 6 (1773–6): 676. On Catching Cold 1773; 62.
23. Davidson, Tish, Teresa G. Odle. «Common Cold». The Gale Encyclopedia of Medicine 2, Detroit: Gale 2006; p. 955–9.
24. Revision of the International Classification of Diseases (ICD). World Health Organization. Retrieved 2010.
Авторы
С.Л.Бабак1,2, М.В.Горбунова1,2, А.Г.Малявин2
1 ФПДО Московского государственного медико-стоматологического университета им. А.И.Евдокимова Минздрава РФ;
2 ФГУ Научно-исследовательский институт пульмонологии Федерального медико-биологического агентства России
1 ФПДО Московского государственного медико-стоматологического университета им. А.И.Евдокимова Минздрава РФ;
2 ФГУ Научно-исследовательский институт пульмонологии Федерального медико-биологического агентства России
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.